Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8 Results for "
colony-forming ability
" in MedChemExpress (MCE) Product Catalog:
Products (8)
8 Results for "colony-forming ability" in MCE Product Catalog:
Cat. No.: HY-161117
CAS No.: 1497439-74-3
Target:
Research Areas:
AD-8007 is a blood-brain barrier-permeable ACSS2 inhibitor with human IC50 of 0.89 μM and Kd of 116.6 μM. AD-8007 reduces colony-forming ability, lipid storage levels and FASN protein expression, and induces cancer cell death. AD-8007 shrinks established tumors, acts synergistically with radiotherapy to inhibit tumor growth, reduces tumor burden, causes no obvious toxicity to normal brain tissue, and prolongs survival. AD-8007 exhibits superior metabolic stability. AD-8007 is applicable to research related to breast cancer brain metastasis .
Cat. No.: HY-151915
CAS No.: 3012609-63-8
ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC50 of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC50 of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .
Cat. No.: HY-180848
CAS No.: 3051861-49-2
Target:
Research Areas:
Bcl-2-IN-24 (Compound 11g) is an efficient and selective Bcl-2 inhibitor with a Kd value of 11.3 μM. Bcl-2-IN-24 exhibits anti-proliferative activity against HCT-116 cells and A549 cells. Bcl-2-IN-24 effectively inhibits the colony-forming ability of tumor cells and induces cell apoptosis. Bcl-2-IN-24 can be used for research on colon cancer and lung cancer .
Cat. No.: HY-182789
VEGFR2-IN-86 is a dual VEGFR2/CDK2 inhibitor, with an IC50 of 0.06 μM against VEGFR2 and an IC50 of 0.78 μM against CDK2. VEGFR2-IN-86 induces G-phase cell cycle arrest, reduces colony-forming ability and tumor cell migration capacity, and exerts antiproliferative activity in cancer cells. VEGFR2-IN-86 can be used for the research of breast cancer and prostate cancer .
Cat. No.: HY-183783
PROTAC RET Degrader 2 is a RET degrader with a target IC50 of 0.36 nM. PROTAC RET Degrader 2 is mainly composed of RET-IN-34 (HY-183729) and Thalidomide (HY-14658). PROTAC RET Degrader 2 mediates RET degradation via the ubiquitin-proteasome system. PROTAC RET Degrader 2 induces apoptosis, inhibits colony-forming ability, and exhibits antiproliferative activity in cancer cells. PROTAC RET Degrader 2 suppresses tumor growth in xenograft models. PROTAC RET Degrader 2 can be used in research related to medullary thyroid carcinoma, papillary thyroid carcinoma, and RET fusion-positive lung adenocarcinoma .
Cat. No.: HY-N20674
CAS No.: 76472-89-4
Category:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
